Overview
- Topline Phase 3 MagnetisMM‑5 results showed a statistically significant, clinically meaningful gain in progression‑free survival versus DPd, a common three‑drug standard.
- Pfizer said the benefit cleared the study’s preset interim efficacy target, with most patients on Elrexfio not seeing their disease progress at this cut of the data.
- Reported side effects matched Elrexfio’s known safety profile, with no new safety signals disclosed in the interim readout.
- The study remains active to measure overall survival, which will help determine potential label updates and how doctors use the drug.
- Elrexfio is already approved in more than 35 countries for multiple myeloma, a blood cancer that affects about 36,000 people each year in the U.S. and roughly 187,000 worldwide.